Solentim China Team

Solentim expands global reach, opening new operation in China

Bournemouth, UK, 23rd February 2021 / Solentim, the trusted global leader in cell therapy workflows enabling the creation, isolation and characterization of high value cells, announces the opening of a new office in Shanghai. Solentim China is a joint venture with its longstanding distribution partner Trio Biotech Co, and will enhance support for customers and expand …

Read more Solentim expands global reach, opening new operation in China

Redefining cell line development

Following the launch of Solentim’s new ICON™ instrument and dedicated STUDIUS™ software, the two of which complete the company’s cutting-edge ecosystem, we spoke with Dr Ian Taylor, Chief Business Officer, Solentim, to find out what this means for cell line development and the future of antibody therapeutics.

Read more Redefining cell line development

Why Evercell Bio chose VIPS: a new workflow for hiPSC in cell therapy

Philip D. Manos, Founder and President of EverCell Bio, Natick, Massachusetts, USA “Our mission is to accelerate the implementation of human and disease-specific stem cell technologies for drug discovery and personalized medicine” EverCell Bio is a single-source provider of customized services for the application of stem cell technology in cell therapy. EverCell offers human cell-modelling …

Read more Why Evercell Bio chose VIPS: a new workflow for hiPSC in cell therapy

Solentim to launch the ICON™ in 2021

Solentim is happy to announce that its new Cell Line Development platform, the ICON, will launch early 2021. For over a decade, Solentim has provided leading solutions to create, isolate and characterize the highest value cells, accelerating the development of new biological medicines and therapies around the world, in cell line development, vaccine research, stem …

Read more Solentim to launch the ICON™ in 2021

Solentim and ATUM to bundle Leap-In Transposase® with the VIPS™ single cell cloning instrument for cell line development

Bournemouth, UK and Newark, CA, USA, 20th April 2020 / Solentim, a global leader in cell line development (CLD) instrumentation, and bioengineering company ATUM, today announced that Solentim will bundle access to the Leap-In Transposase® platform together with the Solentim VIPS™ single cell cloning instrument. Leap-In Transposases enable stable high titer clones to be isolated whilst screening …

Read more Solentim and ATUM to bundle Leap-In Transposase® with the VIPS™ single cell cloning instrument for cell line development

Proof of clonality and its importance in stable cell line development

What is clonality and why is it important Clonality is a crucial step in stable cell line development (CLD) for biotherapeutic workflows and one closely monitored by the medicines’ regulators. Their questions lead to two possible conclusions about how they view the importance of clonality1: Assurance of “clonality” of stable production cell lines is of …

Read more Proof of clonality and its importance in stable cell line development